FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900981012> ?p ?o ?g. }

• W2900981012 endingPage "790" @default.
• W2900981012 startingPage "773" @default.
• W2900981012 abstract "The aim of this study was to evaluate the cost-effectiveness of ribociclib compared to palbociclib, both in combination with letrozole, in the first-line treatment of postmenopausal women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (ABC) from the perspective of the Spanish National Health System (NHS).Disease progression was simulated with a partitioned survival model developed from the parameterization and extrapolation of survival curves of postmenopausal women with HR+/HER2- ABC from clinical trials with ribociclib or palbociclib, both in combination with letrozole. The model was structured on the basis of three health states (progression-free, progressed disease, and death), with a 1-month cycle length and inclusion of subsequent treatments administered for disease progression, over a time horizon of 15 years. Clinical, economic, and quality of life parameters were drawn from clinical trials and the literature. The use of resources and clinical practice in the Spanish setting was validated by a panel of experts. The Spanish NHS perspective was adopted, taking into account exclusively direct health costs from 2017 expressed in Euros. Drug prices used were the reported ex-factory prices. Uncertainty of the parameters and robustness of the results were evaluated using deterministic and probabilistic sensitivity analyses (2,000 iterations).This cost-effectiveness analysis showed a greater benefit (0.437 and 0.285 life-years gained [LYGs] and quality-adjusted life years [QALYs] gained, respectively) and a slightly higher cost (€439.86) for ribociclib+letrozole compared to palbociclib+letrozole. The resulting incremental cost-effectiveness and cost-utility ratios were €1,007.69 per LYG and €1,543.62 per QALY gained, respectively. The results of the multiple sensitivity analyses showed limited dispersion of the outcomes, thus corroborating their robustness.From the NHS perspective, considering the most commonly established willingness-to-pay thresholds in the Spanish setting, ribociclib+letrozole would represent a cost-effective therapeutic option compared to palbociclib+letrozole in the first-line treatment of HR+/HER2- ABC in postmenopausal women." @default.
• W2900981012 created "2018-11-29" @default.
• W2900981012 creator A5012741027 @default.
• W2900981012 creator A5018645050 @default.
• W2900981012 creator A5028408282 @default.
• W2900981012 creator A5029259865 @default.
• W2900981012 creator A5052830414 @default.
• W2900981012 date "2018-11-01" @default.
• W2900981012 modified "2023-10-15" @default.
• W2900981012 title "Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2&ndash; advanced or metastatic breast cancer in Spain" @default.
• W2900981012 cites W1464936406 @default.
• W2900981012 cites W1536583711 @default.
• W2900981012 cites W1593763867 @default.
• W2900981012 cites W1605523334 @default.
• W2900981012 cites W1757407923 @default.
• W2900981012 cites W1987489604 @default.
• W2900981012 cites W2020677481 @default.
• W2900981012 cites W2025029039 @default.
• W2900981012 cites W2034329318 @default.
• W2900981012 cites W2044178975 @default.
• W2900981012 cites W2044715315 @default.
• W2900981012 cites W2061382057 @default.
• W2900981012 cites W2066378779 @default.
• W2900981012 cites W2077776471 @default.
• W2900981012 cites W2083375435 @default.
• W2900981012 cites W2086540370 @default.
• W2900981012 cites W2092696843 @default.
• W2900981012 cites W2092901728 @default.
• W2900981012 cites W2120603700 @default.
• W2900981012 cites W2122508557 @default.
• W2900981012 cites W2138194420 @default.
• W2900981012 cites W2140741940 @default.
• W2900981012 cites W2147608714 @default.
• W2900981012 cites W2168083201 @default.
• W2900981012 cites W2189179298 @default.
• W2900981012 cites W2204819311 @default.
• W2900981012 cites W2295971206 @default.
• W2900981012 cites W2336794604 @default.
• W2900981012 cites W2346624277 @default.
• W2900981012 cites W2417413343 @default.
• W2900981012 cites W2528767298 @default.
• W2900981012 cites W2552099557 @default.
• W2900981012 cites W2560635244 @default.
• W2900981012 cites W2580189873 @default.
• W2900981012 cites W2735183683 @default.
• W2900981012 cites W2754512231 @default.
• W2900981012 cites W3016908890 @default.
• W2900981012 doi "https://doi.org/10.2147/ceor.s178934" @default.
• W2900981012 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6241542" @default.
• W2900981012 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30532569" @default.
• W2900981012 hasPublicationYear "2018" @default.
• W2900981012 type Work @default.
• W2900981012 sameAs 2900981012 @default.
• W2900981012 citedByCount "22" @default.
• W2900981012 countsByYear W29009810122018 @default.
• W2900981012 countsByYear W29009810122019 @default.
• W2900981012 countsByYear W29009810122020 @default.
• W2900981012 countsByYear W29009810122021 @default.
• W2900981012 countsByYear W29009810122022 @default.
• W2900981012 countsByYear W29009810122023 @default.
• W2900981012 crossrefType "journal-article" @default.
• W2900981012 hasAuthorship W2900981012A5012741027 @default.
• W2900981012 hasAuthorship W2900981012A5018645050 @default.
• W2900981012 hasAuthorship W2900981012A5028408282 @default.
• W2900981012 hasAuthorship W2900981012A5029259865 @default.
• W2900981012 hasAuthorship W2900981012A5052830414 @default.
• W2900981012 hasBestOaLocation W29009810121 @default.
• W2900981012 hasConcept C112930515 @default.
• W2900981012 hasConcept C121608353 @default.
• W2900981012 hasConcept C126322002 @default.
• W2900981012 hasConcept C143998085 @default.
• W2900981012 hasConcept C159110408 @default.
• W2900981012 hasConcept C2775930923 @default.
• W2900981012 hasConcept C2777176818 @default.
• W2900981012 hasConcept C2778812593 @default.
• W2900981012 hasConcept C2779744173 @default.
• W2900981012 hasConcept C2779951463 @default.
• W2900981012 hasConcept C29456083 @default.
• W2900981012 hasConcept C3019080777 @default.
• W2900981012 hasConcept C515549039 @default.
• W2900981012 hasConcept C530470458 @default.
• W2900981012 hasConcept C535046627 @default.
• W2900981012 hasConcept C64332521 @default.
• W2900981012 hasConcept C71924100 @default.
• W2900981012 hasConceptScore W2900981012C112930515 @default.
• W2900981012 hasConceptScore W2900981012C121608353 @default.
• W2900981012 hasConceptScore W2900981012C126322002 @default.
• W2900981012 hasConceptScore W2900981012C143998085 @default.
• W2900981012 hasConceptScore W2900981012C159110408 @default.
• W2900981012 hasConceptScore W2900981012C2775930923 @default.
• W2900981012 hasConceptScore W2900981012C2777176818 @default.
• W2900981012 hasConceptScore W2900981012C2778812593 @default.
• W2900981012 hasConceptScore W2900981012C2779744173 @default.
• W2900981012 hasConceptScore W2900981012C2779951463 @default.
• W2900981012 hasConceptScore W2900981012C29456083 @default.
• W2900981012 hasConceptScore W2900981012C3019080777 @default.
• W2900981012 hasConceptScore W2900981012C515549039 @default.
• W2900981012 hasConceptScore W2900981012C530470458 @default.

• next